Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 2Gowling WLG (Canada) LLP

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

Gowling WLG (Canada) LLP

arrow
Aus. Peptide Conference
Not Confirmed

Gowling WLG (Canada) LLP

Country
arrow
Aus. Peptide Conference
Not Confirmed

LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN

Brand Name : PLUVICTO

Patent Number : 2924360

Filing Date : 2014-10-17

Strength per Unit : 1 000 MBq / mL at calibration

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2034-10-17

Date Granted : 2022-04-26

blank

02

Gowling WLG (Canada) LLP

arrow
Aus. Peptide Conference
Not Confirmed

Gowling WLG (Canada) LLP

Country
arrow
Aus. Peptide Conference
Not Confirmed

LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN

Brand Name : PLUVICTO

Patent Number : 2891476

Filing Date : 2013-11-14

Strength per Unit : 1 000 MBq / mL at calibration

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2033-11-14

Date Granted : 2022-07-05

blank